DIFFERENT SKILLS.
A COMMON GOAL.
INTERGEN connects research groups from different regions of Brazil to develop knowledge, technologies, and new approaches in gene therapy.
From basic research to preclinical development, different specialties work together to strengthen the country's scientific and technological capacity.
RESEARCH AREAS
WHERE WE OPERATE
The research developed by the INTERGEN groups covers different diseases and possibilities for the application of gene therapy.
CANCER
Development of gene therapy and immunotherapy strategies aimed at the study and treatment of tumors.
IMMUNOTHERAPY
Genetic modification of cells and development of approaches capable of directing or enhancing immune system responses.
VACCINES
Development and research of DNA, RNA, and other vaccine platforms for prophylactic and therapeutic applications.
NEURODEGENERATIVE DISEASES
Estratégias de neuroproteção e regeneração baseadas em transferência e modulação gênica.
ISCHEMIC AND MUSCULAR DISEASES
Development of gene and cellular approaches aimed at tissue regeneration and recovery.
HEMATOPOIETIC DISEASES
TICAS
Research into therapy and gene editing strategies applied to diseases of the hematopoietic system.
Rare Diseases
Development of in vivo and ex vivo gene editing therapies and strategies for diseases of genetic origin .
TECHNOLOGY
DIFFERENT TECHNOLOGIES FOR DIFFERENT CHALLENGES.
Gene therapy does not depend on a single technology. The INTERGEN groups develop and use different strategies to modify, transport, or regulate genetic material in cells. This technological diversity allows for the investigation of distinct pathways according to each research objective.
VIRAL VECTORS
Desenvolvimento, produção e aprimoramento de vetores como adenovírus, lentivírus, retrovírus e vírus adeno-associados recombinantes (rAAV).
NON-VIRAL VECTORS
Desenvolvimento de sistemas como vetores plasmidiais, minicírculos e materiais poliméricos para transferência de material genético.
EDITING AND GENETIC REGULATION
Use and development of tools such as CRISPR/Cas, CRISPRa, CRISPRoff, Base Editing, and other gene modification and regulation strategies.
NANOCARRIERS
Development of nanoparticles and delivery systems for DNA, RNA, and other components used in gene therapy.
PSEUDOVIRAL PARTICLES
(VLPs)
Use of virus-like particles as platforms for delivering components and genetic material.
GENETICALLY MODIFIED CELLS
Cell modification for applications in gene therapy, immunotherapy, and other advanced therapies.
TISSUE ENGINEERING AND EXPERIMENTAL MODELS
The use of cell cultures, 3D models, biomaterials, bioprinting, and experimental models to study and evaluate new therapeutic strategies.